首页|达格列净联合常规药物治疗T2DM合并冠心病的效果及对患者心功能的影响

达格列净联合常规药物治疗T2DM合并冠心病的效果及对患者心功能的影响

扫码查看
目的 探讨达格列净联合常规药物治疗2型糖尿病(T2DM)合并冠心病(CHD)的效果及对患者心功能的影响.方法 将2021年9月至2023年5月我院收治的86例T2DM合并CHD患者随机分为两组.对照组采用常规药物治疗,观察组在对照组基础上采用达格列净治疗.比较两组的NYHA分级、HbA1c、hs-CRP及心功能指标.结果 治疗后3个月,观察组心功能优于对照组(P<0.05);两组HbA1c、hs-CRP、NT-proBNP水平降低,且观察组HbA1c、hs-CRP、NT-proBNP水平低于对照组(P<0.05).结论 达格列净联合常规药物治疗T2DM合并CHD可降低患者血糖水平,抑制机体炎性因子分泌,改善心功能.
Effect of Dapagliflozin Combined with Routine Drugs on T2DM Complicated with Coronary Heart Disease and the Influence on Patients'Cardiac Function
Objective To explore the effect of dapagliflozin combined with routine drugs in the treatment of type 2 diabetes mellitus(T2DM)complicated with coronary heart disease(CHD)and the influence on patients'cardiac function.Methods 86 patients with T2DM complicated with CHD admitted to our hospital from September 2021 to May 2023 were selected and divided into two groups according to randomization method.The control group was treated with routine drugs,and the observation group was treated with dapagliflozin on the basis of the control group.The NYHA grading,HbA1c,hs-CRP and cardiac function indicators were compared between the two groups.Results After 3 months of treatment,the cardiac function of the observation group was better than that of control group(P<0.05);The HbA1c,hs-CRP and NTproBNP levels of both groups decreased,and the HbA1c,hs-CRP and NTproBNP levels of the observation group were lower than those of the control group(P<0.05).Conclusions Dapagliflozin combined with routine drugs in the treatment of T2DM patients complicated with CHD can reduce the blood glucose,inhibit the secretion of inflammatory factors and improve the cardiac function.

DapagliflozinType 2 diabetes mellitusCoronary heart disease

余蓬燕、赵芳芳、冯小胜、梅桂丽、戴慧慧

展开 >

博爱县人民医院内分泌科,河南焦作 454450

达格列净 2型糖尿病 冠心病

2024

临床医学工程
国家医疗保健器具工程技术研究中心

临床医学工程

影响因子:0.193
ISSN:1674-4659
年,卷(期):2024.31(3)
  • 8